

1 / 33

1 **Name of Journal:** *World Journal of Clinical Oncology*

Manuscript NO: 53938

Manuscript Type: REVIEW

B-cell lymphoma-2 inhibition and resistance in acute myeloid leukemia

Lindsay Wilde, Sabarina Ramanathan, Margaret Kasner

Abstract

Spurred by better understanding of disease biology, improvements in molecular diagnostics, and the development of targeted therapies, the treatment of acute myeloid leukemia (AML) has undergone significant evolution in recent years. Arguably, the most exciting shift has come from the success of treatment with the B-cell lymphoma-2 inhibitor venetoclax. When given in combination with a hypomethylating agent or low dose cytarabine, venetoclax demonstrates high response rates, some of which are durable. In spite of this, relapses after venetoclax treatment are common, and much

Match Overview

Match Number	Source	Words	Percentage
1	Internet crawled on 28-Jun-2020 f6publishing.blob.core.windows.net	151 words	3%
2	Internet crawled on 03-Jun-2017 embor.embopress.org	49 words	1%
3	Crossref Mark C Genovese, Roy Fleischmann, Daniel Furst, Namiet a Janssen et al. "Efficacy and safety of olokizumab in patie	30 words	1%
4	Crossref Brenda Chyla, Naval Daver, Kelly Doyle, Evelyn McKeegan et al. "Genetic biomarkers of sensitivity and resistance to ...	26 words	1%
5	Crossref Daniel A. Pollyea, Maria Amaya, Paolo Strati, Marina Y. Ko... opleva. "Venetoclax for AML: changing the treatment parad	26 words	1%
6	Internet crawled on 26-Dec-2016 www.la-press.com www.la-press.com	19 words	<1%
7	Crossref Xin Li, Lan Xu, Xianfu Shen, Jiayi Cai, Jia Liu, Tingyu Yin, Fe i Xiao, Fangyuan Chen, Hua Zhong. "Up-regulated miR-146	18 words	<1%
8	Crossref Mohamed Rahmani, Jewel Nkwocha, Elisa Hawkins, Xinya n Pei et al. "Cotargeting BCL-2 and PI3K Induces BAX-De...	17 words	<1%



ALL

IMAGES

VIDEOS

60,600 Results

Any time ▾

Bcl-2 Inhibition to Overcome Resistance to Chemo- and ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6321604>

Dec 08, 2018 · Studies published to date show the clear implication of **aberrant Bcl-2 proteins' expression** in **carcinogenesis** and **apoptosis resistance** after **chemo-** or **immuno-therapies**, which supports the development of **Bcl-2-targeting strategies** to **overcome resistance** and improve a patient's clinical management and survival.

Cited by: 7

Author: Marilina García-Aranda, Elisabet Pérez...

Publish Year: 2018

Overcoming adaptive therapy resistance in AML by targeting ...

<https://stm.sciencemag.org/content/11/508/eaaw8828> ▾

Sep 04, 2019 · **Acute myeloid leukemia** is an aggressive cancer that can be difficult to **treat** because of rapidly evolving **therapeutic resistance**. Melgar et al. focused on a subtype of **acute myeloid leukemia** characterized by mutations in a gene called FLT3. Although **FLT3 inhibitors** can **target oncogenic signaling** pathways in this cancer, their effects do not last.

Cited by: 2

Author: Katelyn Melgar, Morgan M. Walker, La...

Publish Year: 2019

A-1210477, a selective MCL-1 inhibitor, overcomes ABT-737 ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6781566>

Sep 19, 2019 · Since the overlapping of **anti-apoptotic** proteins in the **BCL-2** family serves an important role in **therapeutic resistance**, the simultaneous **targeting** of the **anti-apoptotic proteins** of **BCL-2** family could **overcome drug resistance** (37, 38).

Author: Qing Wang, Siguo Hao **Publish Year:** 2019

国内版

国际版

B-cell lymphoma-2 Inhibition and Resistance in Acute Myeloid Lei



ALL

IMAGES

VIDEOS

277,000 Results

Any time ▾

Inhibition of mitochondrial translation overcomes ...

<https://www.ncbi.nlm.nih.gov/pubmed/31666400>

Oct 30, 2019 · **Venetoclax** is a specific B cell lymphoma 2 (BCL-2) inhibitor with promising activity against acute myeloid leukemia (AML), but its clinical efficacy as a single agent or in combination with hypomethylating agents (HMAs), such as azacitidine, is hampered by intrinsic and acquired resistance. Here, we performed

Cited by: 2

Author: David Sharon, Severine Cathelin, Sara Miral...

Publish Year: 2019

HOX gene expression predicts response to BCL-2 inhibition ...

<https://www.nature.com/articles/leu2016222>

Aug 08, 2016 · **Inhibitors of B-cell lymphoma-2 (BCL-2)** such as venetoclax (ABT-199) and navitoclax (ABT-263) are clinically explored in several cancer types, including **acute myeloid leukemia (AML)**, to ...

Cited by: 31

Author: M Kontro, A Kumar, M M Majumder, S Eldfo...

Publish Year: 2017

Images of B-cell Lymphoma-2 Inhibition and resistance in acute m...

<bing.com/images>



B-cell lymphoma-2 inhibition and resistance in acute myeloid leuke



ALL IMAGES VIDEOS MAPS NEWS SHOPPING

287,000 Results Any time ▾

Venetoclax

Venetoclax is a specific B cell lymphoma 2 (BCL-2) inhibitor with promising activity against acute myeloid leukemia (AML), but its clinical efficacy as a single agent or in combination with hypomethylating agents (HMAs), such as azacitidine, is hampered by intrinsic and acquired resistance.

Author: David Sharon, Severine Cathelin, Sara Mirali, Justin M. Di Trani, David J. Yanofsky, Kristine A. Keo...

Cited by: 4

Publish Year: 2019

[Inhibition of mitochondrial translation overcomes ...](#)

www.ncbi.nlm.nih.gov/pubmed/31666400

Was this helpful?

[HOX gene expression predicts response to BCL-2 inhibition ...](#)

<https://www.ncbi.nlm.nih.gov/pubmed/27499136>

Inhibitors of B-cell lymphoma-2 (BCL-2) such as venetoclax (ABT-199) and navitoclax (ABT-263) are clinically explored in several cancer types, including **acute myeloid leukemia** (AML), to selectively induce apoptosis in cancer cells.

Cited by: 32 **Author:** M Kontro, A Kumar, M M Majumder, S Eld...

Publish Year: 2017

[HOX gene expression predicts response to BCL-2 inhibition ...](#)

<https://www.nature.com/articles/leu2016222>

Aug 08, 2016 · **Inhibitors of B-cell lymphoma-2** (BCL-2) such as venetoclax (ABT-199) and navitoclax (ABT-263) are clinically explored in several cancer types, including **acute myeloid leukemia** (AML), to ...